69% Pharma Marketers Prefer Programmatic Messaging Platforms in the US for Improved HCP Reach EHR and telehealth platforms leveraging programmatic solutions to better engage healthcare experts, creating huge opportunity for pharma brands PARSIPPANY, NJ – January 13, 2022 – Amid the turmoil of the recurring waves of the pandemic, pharma marketers are shifting their focus […]
If you are not happy with the results below please do another search
50 search results for:
Prellis Biologics entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing the Bay Area biotechnology company’s first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO).
Evoke announced three key leadership hires to the global health and wellness agency’s executive team.
imre named Anna Kotis as the new president of imre Health, as the digital powerhouse continues to elevate its life sciences offerings and catalyze year-over-year growth into more robust digital AOR engagements.
President Joe Biden on January 13 said he will deploy more military health workers to six U.S. states beginning next week, and give Americans free masks and more free tests to tackle the fast-spreading Omicron variant around the country.
Poorer nations during December 2021 rejected more than 100 million doses of COVID-19 vaccines distributed by the global program COVAX, mainly due to their rapid expiration date, a UNICEF official said on January 13.
A record 14.1 million Americans signed up for health insurance since the start of the 2022 open enrollment period in November 2021, the U.S. health department said on January 13.
NRx Pharmaceuticals filed a counter lawsuit against Relief Therapeutics, the company it initially partnered with to develop the experimental COVID-19 treatment aviptadil, which was submitted to the U.S. Food and Drug Administration for Emergency Use Authorization.
GSK and Vir Biotechnology said on January 13 they are seeking an expansion to the U.S. approval of their antibody-based COVID-19 treatment to include an option for the therapy to be given as a shot in the arm.
AstraZeneca said on January 13 that preliminary data from a trial showed that the company’s COVID-19 shot Vaxzevria generated an increase in antibodies against the Omicron and other variants when given as a third booster dose.